Matched TA-TAVR patients experienced more adverse procedural events , longer length of stay ( @ versus @ days ; P < @ ) , and slower recovery ( New York Heart Association class I , @ % versus @ % at @ days , equalizing by @ months at @ % versus @ % ) ; stroke risk was similar ( @ % versus @ % at @ days and @ % versus @ % at @ years ) ; mortality was elevated for the first @ postprocedural months ( @ % versus @ % ; P = @ ) ; but aortic regurgitation was less ( @ % versus @ % mild and @ % versus @ % moderate to severe at discharge , P = @ ; @ % versus @ % mild and @ % versus @ % moderate to severe at @ months , P < @ ) .